Back to results
US 2026/0295080 A1Published application
Lipids and nanoparticle formulations thereof
AssigneeArcturus Therapeutics, Inc.
InventorsKumar Rajappan, Steven P. Tanis, Sean S. Sullivan
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and methods thereof.
Claims43
A compound of Formula I:
- wherein
- X1, X2, and X3 are each independently O or S,
- Ra, Rb, and Rc are each independently H, or C1-6 alkyl, or
- Ra is H or C1-6 alkyl, and Rb and Rc taken together with the N they are attached to form a 3- to 8-membered heterocyclyl, the heterocyclyl being optionally substituted with one or more C1-3 alkyl,
- n is 2 to 6,
- either
- (i) R1 is
- and R2 is
- wherein
- Y1 is absent, O, or S,
- L1 is C3-40 alkyl, C3-40 alkenyl, or C3-40 alkynyl,
- either
- (a) Y2 is absent or C1-4 alkylene, W is absent, O, or S, and L2 is selected from C3-40 alkyl, C3-40 alkenyl, and C3-40 alkynyl, optionally the alkyl, alkenyl, and alkynyl are branched, or
- (b) Y2 is C1-4 alkylene, optionally substituted with oxo, W is absent, and L2 is cholesterol or cholesterol derivative attached to Y2 via an O atom of the cholesterol or via an O or S atom of the cholesterol derivative;
- or
- (ii) R1 is
- and R2 is
- wherein
- Y1 is absent, O, or S,
- L1 is C3-40 alkyl, C3-40 alkenyl, or C3-40 alkynyl,
- Y2 is C1-4 alkylene, W is absent or carbonyl, and L2 is cholesterol or cholesterol derivative attached to Y2 via an O atom of the cholesterol or via an O or S atom of the cholesterol derivative.
18 more elements
-15. (canceled)
-34. (canceled)
-43. (canceled)
(canceled)
-54. (canceled)
-65. (canceled)
-68. (canceled)
-76. (canceled)
-82. (canceled)
-88. (canceled)
-95. (canceled)
-98. (canceled)
-103. (canceled)
-111. (canceled)
-114. (canceled)
116-117. (canceled)
Dependencies are inferred from the claim text.